Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

9 Out Of 10 US Doctors Willing To Prescribe Biosimilars

XTALKS VITALS NEWS

Biosimilar

Ninety-one percent of US physicians would be willing to prescribe a biosimilar over its branded biologic, given the right circumstances.

Share this!

November 4, 2016 | by Sarah Hand, M.Sc.

According to a survey conducted by the Biosimilars Forum – a nonprofit organization aimed at advancing biosimilars in the US – 91 percent of US physicians would be willing to prescribe a biosimilar over its branded biologic, given the right circumstances. However, the survey also found that doctors were uncertain about the regulations surrounding the approval process of biosimilars, suggesting that they could benefit from more education about the drugs.

The survey was conducted to assess 1,201 doctors’ perception on biosimilars. These doctors were chosen to participate in the survey based on the fact that they routinely prescribed biologic drugs to their patients.

Right now, only four biosimilar drugs have received regulatory approval in the US, with just one of the drugs – Novartis’ Zarxio – currently available on the market. The hope is that these biosimilars will offer a less-expensive treatment option for patients currently taking pricey branded biologics.

While a biosimilar must demonstrate a high level of similarity to its reference product, without showing any differences in safety or efficacy in order to gain marketing approval, only 45 percent of doctors polled agreed that biosimilars would be “safe and appropriate for use in naive and existing patients.” This result suggests that many physicians may be unaware of the stringencies governing US Food and Drug Administration (FDA) approval of biosimilars.



The survey found that most physicians were unclear on how the regulatory approval process differs from that of branded drugs. Biosimilars are primarily assessed based on their level of similarity to the reference product.

Using this evidence of similarity, the FDA can extrapolate how effective it might be at treating the same indications as the biologic. Only 12 percent of physicians who participated in this survey said they were comfortable with the idea of extrapolating data.

One third of the doctors believed that a pharmacist could swap a biologic prescription for a biosimilar, as is the case with generic drugs. While this is theoretically possible, all four of the approved biosimilars have not been granted interchangeable status which would allow pharmacists to exchange one for the other.

At the time of the survey, only Novartis’ Zarxio was FDA-approved, leading the organizers to speculate that physicians may be more knowledgeable about the drug class now that there are other biosimilars entering the market. Amgen, Pfizer, Novartis and Samsung Bioepis are just some of the big-name pharma companies that comprise the Biosimilars Forum.


Keywords: Prescription, Biosimilar, Biologic


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.